Emerging evidence supports a hypothesized role for the α7-nicotinic acetylcholine receptor (α7-nAChR) in the pathophysiology of Alzheimer's disease. 18F-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-18F-fluorodibenzo[b,d]thiophene 5,5-dioxide) is a radioligand for estimating the availability of α7-nAChR in the brain in vivo with PET. Methods: In this cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to dementia, and 17 cognitively intact, elderly controls completed 18F-ASEM PET. For each participant, binding in each region of interest was estimated using Logan graphical analysis with a metabolite-corrected arterial input function. Results: Higher 18F-ASEM binding was observed in MCI patients than in controls across all regions, supporting higher availability of α7-nAChR in MCI. 18F-ASEM binding was not associated with verbal memory in this small MCI sample. Conclusion: These data support use of 18F-ASEM PET to examine further the relationship between α7-nAChR availability and MCI.
Emerging evidence supports a hypothesized role for the α7-nicotinic acetylcholine receptor (α7-nAChR) in the pathophysiology of Alzheimer's disease. 18F-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-18F-fluorodibenzo[b,d]thiophene 5,5-dioxide) is a radioligand for estimating the availability of α7-nAChR in the brain in vivo with PET. Methods: In this cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to dementia, and 17 cognitively intact, elderly controls completed 18F-ASEM PET. For each participant, binding in each region of interest was estimated using Logan graphical analysis with a metabolite-corrected arterial input function. Results: Higher 18F-ASEM binding was observed in MCI patients than in controls across all regions, supporting higher availability of α7-nAChR in MCI. 18F-ASEM binding was not associated with verbal memory in this small MCI sample. Conclusion: These data support use of 18F-ASEM PET to examine further the relationship between α7-nAChR availability and MCI.
Authors: H W Müller-Gärtner; J M Links; J L Prince; R N Bryan; E McVeigh; J P Leal; C Davatzikos; J J Frost Journal: J Cereb Blood Flow Metab Date: 1992-07 Impact factor: 6.200
Authors: Jennifer Coughlin; Yong Du; Jeffrey L Crawford; Leah H Rubin; Babak Behnam Azad; Wojciech G Lesniak; Andrew G Horti; David J Schretlen; Akira Sawa; Martin G Pomper Journal: J Nucl Med Date: 2018-12-20 Impact factor: 10.057
Authors: J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley Journal: J Cereb Blood Flow Metab Date: 1990-09 Impact factor: 6.200
Authors: Andrew G Horti; Yongjun Gao; Hiroto Kuwabara; Yuchuan Wang; Sofya Abazyan; Robert P Yasuda; Thao Tran; Yingxian Xiao; Niaz Sahibzada; Daniel P Holt; Kenneth J Kellar; Mikhail V Pletnikov; Martin G Pomper; Dean F Wong; Robert F Dannals Journal: J Nucl Med Date: 2014-02-20 Impact factor: 10.057
Authors: Jennifer M Coughlin; Yong Du; Hailey B Rosenthal; Stephanie Slania; Soo Min Koo; Andrew Park; Ghedem Solomon; Melin Vranesic; Inga Antonsdottir; Caroline L Speck; Kelly Rootes-Murdy; Alexandria Lerner; Steven P Rowe; Yuchuan Wang; Wojciech G Lesniak; Il Minn; Arnold Bakker; Gwenn S Smith; Robert F Dannals; Hiroto Kuwabara; Andrew Horti; Dean F Wong; Martin G Pomper Journal: Neuroimage Date: 2017-10-07 Impact factor: 6.556
Authors: Shannon L Risacher; Sungeun Kim; Li Shen; Kwangsik Nho; Tatiana Foroud; Robert C Green; Ronald C Petersen; Clifford R Jack; Paul S Aisen; Robert A Koeppe; William J Jagust; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Andrew J Saykin Journal: Front Aging Neurosci Date: 2013-04-01 Impact factor: 5.750
Authors: Cornelius K Donat; Henrik H Hansen; Hanne D Hansen; Ronnie C Mease; Andrew G Horti; Martin G Pomper; Elina T L'Estrade; Matthias M Herth; Dan Peters; Gitte M Knudsen; Jens D Mikkelsen Journal: Molecules Date: 2020-03-20 Impact factor: 4.411